ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com
1. 6ÔÂ19ÈÕ£¬¾Ý¹ú¼ÒÒ©¼à¾Ö¹ÙÍø£¬µÏÕÜÒ½Ò©¸ßÑ¡ÔñÐÔJAK1ÒÖÖÆ¼Á¸êÀûÎôÌæÄᣨÉÌÆ·ÃûΪ¸ßÈðÕÜ£©»ñÅú£¬ÓÃÓÚÖÎÁƸ´¾ÙÊÂÖÎÐÔÍâÖÜTϸ°ûÁܰÍÁö£¨r/r PTCL£©¡£¸ßÈðÕܳÉΪ¡°È«ÇòÊ׸öÇÒΨһ¡±Õë¶ÔPTCLµÄJAK1ÒÖÖÆ¼Á£¬Ò²ÊÇÒÑÍùÊ®ÄêÀ´£¬¸ÃÖÎÁÆÁìÓòÉÏÊеÄÊ׸öÁ¢ÒìÒ©¡£
2. 6ÔÂ20ÈÕ£¬Ð»ªÖÆÒ©Ðû²¼Í¨¸æ³Æ£¬¹«Ë¾²úÆ·ÆÕÈð°ÍÁÖ½ºÄÒ£¨150mg,75mg£©»ñÅúÉÏÊУ¬ÓÃÓÚÖÎÁÆ´ø×´ðåÕîºóÉñ¾Í´¡¢ÏËά¼¡Í´¡£
3. 6ÔÂ20ÈÕ ÖйúÉúÎïÖÆÒ©×òÈÕÐû²¼£¬1ÀàÁ¢ÒìÒ©èÛéÚËáÒÀ·î°¢¿Ë½º¡°Envonalkib (TQ-B3139)¡±»ñÅúÉÏÊУ¬ÓÃÓÚδ¾Óɼä±äÐÔÁܰÍÁö¼¤Ã¸(ALK)ÒÖÖÆ¼ÁÖÎÁƵÄALKÑôÐԵľֲ¿ÍíÆÚ»ò×ªÒÆÐÔ·ÇСϸ°û·Î°©(NSCLC)»¼ÕßµÄÖÎÁÆ¡£
4. 6ÔÂ19ÈÕ£¬CDE¹ÙÍø¹«Ê¾£¬¾¢·½Ò½Ò©ÉêÇëµÄ1ÀàÐÂÒ©GFH375Ƭ»ñÅúÁÙ´²£¬Ä⿪·¢ÖÎÁÆKRAS G12DÍ»±äÑôÐÔµÄÍíÆÚʵÌåÁö»¼Õß¡£Æ¾Ö¤¾¢·½Ò½Ò©¹ûÕæ×ÊÁÏ£¬GFH375ƬΪһ¿î¿Ú·þKRAS G12D£¨ON/OFF£©ÒÖÖÆ¼Á¡£
1. ¿ËÈÕ£¬Ò¢ÌÆ£¨ÉϺ££©ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾ÓëâýØûÉúÎï¿Æ¼¼£¨ÉϺ££©ÓÐÏÞ¹«Ë¾Ç©ÊðÁËÓµÓÐÒ¢ÌÆ×ÔÖ÷֪ʶ²úȨµÄȫлùÒò±à¼¹¤¾ßøYolCas12?µÄÉú²úÏúÊÛÔÊÐíÐÒ顣ƾ֤ÐÒéÄÚÈÝ£¬âýØûÉúÎォ»ñµÃÓÉÒ¢ÌÆ×ÔÖ÷Ñз¢µÄ YolCas12?ÔÚ´óÖлªÇøµÄÉú²úÏúÊÛÔÊÐí¡£
1. 6ÔÂ18ÈÕ£¬ÖÐɽ´óѧÈËÀಡ¶¾Ñ§Ñо¿ËùËù³¤ÕÅ»ÔÍŶÓÔÚ Cell Reports Medicine ×îз¢ÎÄ¡£Ö÷Òª¿ª·¢ÁËÒ»ÖÖ»ùÓÚÌúÂѰ׵ÄÄÉÃ×Á£×ÓÒßÃ磬¸ÃÒßÃçͨ¹ýÁ¬ÏµÈËÀàǰÂѰ×ת»¯Ã¸¿Ý²ÝÈܾúËØ 9£¨PCSK9£©×÷Ϊ¿¹Ô£¬ÓÐÓÃÓÕµ¼±¬·¢×ÌÈÅ PCSK9 »îÐԵĿ¹Ì壬´Ó¶ø½µµÍѪÇåÖ¬ÖÊˮƽ£¬¶Ô¿¹¸ßµ¨¹Ì´¼ÑªÖ¢£¬²¢ÔÚ¶¯ÎïÄ£×ÓÖÐÕ¹ÏÖ³öÓÅÒìµÄÇå¾²ÐԺͺã¾ÃÃâÒß³¤ÆÚÐÔ£¬Îª¸ßµ¨¹Ì´¼ÑªÖ¢ºÍÐÄѪ¹Ü¼²²¡µÄÔ¤·ÀºÍÖÎÁÆÌṩÁËÒ»ÖÖеÄÕ½ÂÔ¡£
[1]Fang QN. et al. Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia. Cell Rep Med. 2024 June 18.